Abstract:Background Glioma is a common and aggressive primary malignant cancer known for its high morbidity, mortality, and recurrence rates. Despite this, treatment options for glioma are currently restricted. The dysregulation of RBPs has been linked to the advancement of several types of cancer, but their precise role in glioma evolution is still not fully understood. This study sought to investigate how RBPs may impact the development and prognosis of glioma, with potential implications for prognosis and therapy. Methods RNA-seq profiles of glioma and corresponding clinical data from the CGGA database were initially collected for analysis. Unsupervised clustering was utilized to identify crucial tumor subtypes in glioma development. Subsequent time-series analysis and MS model were employed to track the progression of these identified subtypes. RBPs playing a significant role in glioma progression were then pinpointed using weighted gene co-expression network analysis and Lasso Cox regression models. Functional analysis of these key RBP-related genes was conducted through GSEA. Additionally, the CIBERSORT algorithm was utilized to estimate immune infiltrating cells, while the STRING database was consulted to uncover potential mechanisms of the identified biomarkers. Results Six tumor subgroups were identified and found to be highly homogeneous within each subgroup. The progression stages of these tumor subgroups were determined using time-series analysis and a MS model. Through weighted gene co-expression network analysis, Lasso Cox, and multivariate Cox regression analysis, it was confirmed that BCLAF1 is correlated with survival in glioma patients and is closely linked to glioma progression. Functional annotation suggests that BCLAF1 may impact glioma progression by influencing RNA shearing, which in turn affects the cell cycle, Wnt signaling pathway, and other cancer development pathways. Conclusions The study initially identified six subtypes of glioma progression and assessed their malignancy ranking. Furthermore, it was determined that BCLAF1 could serve as an RBP-related prognostic marker, offering significant implications for the clinical diagnosis and personalized treatment of glioma.

Transcriptome Analyses Reveal Molecular Mechanisms Underlying Phenotypic Differences among Transcriptional Subtypes of Glioblastoma.

Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy.

RNA Modification Patterns Based on Major RNA Modifications Define Tumor Microenvironment Characteristics in Glioblastoma

Single-Cell Transcriptomics Revealed Subtype-Specific Tumor Immune Microenvironments in Human Glioblastomas

Identification of Hub Genes and Regulatory Factors of Glioblastoma Multiforme Subgroups by RNA-seq Data Analysis

Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition

Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Mining multi-omics data for molecular subtyping in gliomas facilitates precise clinical treatment

Molecular Characteristics in MRI-Classified Group 1 Glioblastoma Multiforme

A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes

Prevalence and Clinicopathologic Characteristics of the Molecular Subtypes in Malignant Glioma: A Multi-Institutional Analysis of 941 Cases

Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma

Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype

Integrated Analysis of Multiomics Data Identified Molecular Subtypes and Oxidative Stress-Related Prognostic Biomarkers in Glioblastoma Multiforme

Unique Genome-Wide Map of TCF4 and STAT3 Targets Using ChIP-seq Reveals Their Association with New Molecular Subtypes of Glioblastoma.

Genomic Analysis of Glioblastoma Multiforme Reveals a Key Transcription Factor Signature Relevant to Prognosis and the Immune Processes

Genome-wide Expression Profiling of Glioblastoma Using a Large Combined Cohort.

Integrated regulatory models for inference of subtype‐specific susceptibilities in glioblastoma

Identification and classification of glioma subtypes based on RNA-binding proteins